NCT01919450View on ClinicalTrials.gov

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Myocardial Blood Flow Reserve
Interventions
DRUG

Regadenoson

Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

RADIATION

Rubidium-82

Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Trial Locations (1)

64111

Saint Luke's Hospital Imaging Center, Kansas City

All Listed Sponsors
lead

Timothy M. Bateman, MD

INDUSTRY

NCT01919450 - Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation | Biotech Hunter | Biotech Hunter